Almirall Sofotec GmbH based in Bad Homburg (near Frankfurt/Main, Germany) is the R&D Centre of Excellence for Inhalation Technology within Almirall — a multinational pharmaceutical company continuously expanding in international markets
Almirall Sofotec GmbH based in Bad Homburg (near Frankfurt/Main, Germany) is theR&D Centre of Excellence for Inhalation Technology within Almirall – a multinational pharmaceutical company continuously expanding in international markets. You will benefit from the growth opportunities at Almirall Sofotec, contribute to a team whose products and devices treat a large number of diseases and improve or even save patients lives. We focus on your professional and personal development. At Almirall Sofotec your performance is appreciated – because your well-being means our well-being!
Head of Technology Department
As head of the Technology department you will be responsible for the scientific and organisational leadership of a team of about 20 people. The Technology department performs the galenical development of all Almirall inhalation products from lab size until transfer to production sites worldwide including both formulation and inhaler development. This is performed internally and externally. Development of inhalation products is aimed at the international market including the US. Clinical trial supply manufacture is performed based on cGMP standards.
In addition you will manage a team of engineers working on Almirall’s future inhalation devices and life cycle management of our existing DPI Genuair.
You will operate in close cooperation with other departments in Almirall Sofotec, as well as with the Almirall headquarters in Barcelona.
Budget planning and controlling, setting objectives and securing the leading position of Almirall in inhalation technology are within your responsibilities.
Your background
Are you interested? We look forward to receiving your application.
Almirall Sofotec GmbH
Frau Tanja Rübenstahl • Benzstraße 1 • 61352 Bad Homburg
E-Mail: Tanja.Ruebenstahl@almirall.com
Telefon: +49 (0)6172 6809-3808 • Telefax: +49 (0)6172 6809-1103
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.